Life Sciences

At Jacobs, we’re working toward a better future – for us all

Save to favorites
Share with your friends

Together we transform

We deliver complex manufacturing facilities for clients who are advancing science, developing medicine and creating capacity that impact people’s lives. We assemble the best teams in the world to design, build, qualify and commission first-of-a-kind facilities within accelerated timelines with a relentless focus on safety, quality and cost – overcoming challenges no one else can.

100 +

life sciences projects, representing $50B+ in construction costs
4 K+

global resources
20

ISPE Facility of the Year Awards since 2010
# 1

in pharmaceuticals and Top 500 design firm (Engineering News-Record, 2024)

What we do

We’re supporting our biopharma clients to bring innovative products to market at pace. With a relentless focus on safety, quality and cost, our diverse, global teams and Subject Matter Experts (SMEs) deploy an integrated project delivery (IPD) approach and leverage cutting-edge digital tools to deliver ‘first of a kind’ facilities within accelerated timelines. In this rapidly evolving environment, we’re supporting clients to deliver projects in these emerging areas:

Messenger RNA (mRNA)

mRNA is a rapidly evolving area of medicine with huge potential. United by a sense of shared purpose, we’re working with our biopharma clients, deploying creative thinking and high-level problem solving to accelerate the development and delivery of potentially transformative treatments. The delivery of facilities that are designed for higher production volumes and make treatments accessible to more patients is a crucial step towards revolutionizing modern medicine.
Cell Therapy

As the commercialization of autologous cell-therapy products gathers pace, wider access is becoming a reality. To ensure more people around the world can access these innovative treatments, we are partnering with clients to overcome operational and regulatory challenges as they scale out production.
Gene Therapy

With an increasing number of cell and gene therapy products receiving regulatory approval, there is a burning need to deliver projects that support the growth of groundbreaking treatments. We’re working hand-in-hand with clients to provide a flexible approach to facility design that addresses complex challenges as manufacturers ramp up production capacity.

CDMOs

Contract development and manufacturing organizations (CDMOs) are supporting a seismic shift in Life Sciences, with their highly flexible large-scale facilities increasing production capacity on a massive scale, reducing risk for pharma companies, and guaranteeing hyper-speed project delivery. We’re helping CDMO clients reach these previously unattainable production targets with a flexible approach realized using integrated project delivery (IPD).
Flexible Facilities

Flexibility played a central role in the response to COVID-19, with solutions providers and Life Sciences companies working together at lightning speed to retro-fit existing facilities for vaccines and treatments. This approach is helping to futureproof the sector, enabling companies to scale manufacturing in response to evolving patient needs, providing fast-tracked access to potentially transformative medicines treatments and therapies for patients globally and addressing patient demand for new treatments and therapies.

Explore our projects

Our work continues to positively impact millions of lives with significant projects and programs around the globe.

Meet some of our team

Read more about the talent who make it happen every day.

0:00

Jacobs Senior Electrical Engineer Kevin Lee shares how his work directly impacted his family when his mom needed a drug product that was manufactured in the same facility he worked on – a reminder of how the work we do truly makes a difference.

Read our latest news

From new project wins and milestones to reports, podcasts and industry insights, discover what we’re up to.

From our newsroom

Our insights

How Flexibility Can Deliver ATMP’s Potential

With the emergence of new medical treatments and therapies reaching the market, and thousands of new therapies also in preclinical and clinical stages, pharmaceutical manufacturing companies are looking to implement multi-model and flexible facilities. Jacobs’ Julie Vickers, Todd Rumsey, Peter Cramer and Francesca McBride discuss how to determine compatibility and congruence between primary and alternative modalities to deliver products with different manufacturing requirements and deliver transformative medicines to patients, faster.

Read the article
Regulatory Considerations for Delivering ATMP Multi-Model Facilities

When it comes to the design and operation of multi-modal facilities, adhering to evolving regulatory requirements across varying jurisdictions is a key consideration. Jacobs’ Francesca McBride discuss the regulatory requirements needed to support the production of the following types of therapies and treatments.

Read the article